Netupitantpalonosetron FDC market holds a substantial scope for growth globally. The market is in its growth stage; however, its contribution to the global market is expected to increase significantly within the next six years.High cost is a major limitation to for the growth of the market in developing regions. However, recent innovations, which embed high potential and longer duration of action within the CINV drugs reach a wider segment of audiences. Numerous players are stepping in the CINV market with innovative products. Emerging technology such as novel drugs discovery and innovation of antiemetic therapy are expected to increase the competition in the near future.
List of Key Players
Key players profiled in this report include Acacia Pharma, Helsinn Holding S.A., Heron Therapeutics, Inc., and Eisai Pharmaceutical Pvt Ltd.
Download Sample Report: https://www.alliedmarketresearch.com/request-sample/1831
Key Findings Of The Study
North America dominated the netupitantpalonosetron market, and is expected to grow at a CAGR of 9.9%.
Asia-Pacific shows thehighestgrowthrate, and is estimated to grow at a CAGR of 14.7%.
For Purchase inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/1831
Companies seek technological advancement to lower production cost and to discover new products. For instance, new drug named rolapitant (Varubi) is developed using new technology by Tesaro, a healthcare-based company. It is the company’s first product under CINV drugs segment, which gained significant traction in the netupitant–palonosetron FDC drug market.
Approval of new drugs provides cancer patients with effective treatment for prevention of delayed phase of nausea and vomiting caused by chemotherapy. This is attributed to increase the demand for netupitant–palonosetron FDC drugs during the forecast period.
Geographically, North America was the dominant regional market for netupitant–palonosetron FDC drugs, in terms of revenue, due to growth in incidence of CINV among patients. These drugs are expected to have significant impact on the revenue of the overall market. Approval of new drugs such as rolapitant and Sustol (APF-530) is expected to boost the growth of the CINV drugs in the US market during the forecast period. Europe was the second largest regional market for netupitant–palonosetron FDC drugs, in terms of revenue, due to growth in demand for netupitant–palonosetron FDC drugs among patients.
David Correa 5933 NE Win Sivers Drive 205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 firstname.lastname@example.org
PR-Wirein, Financial Content, iCN Internal Distribution, Research Newswire, English